x
Elara Pharmaceuticals Ltd - Logo
[contact-form-7 404 "Not Found"]

  • The Barn Holly Berry House Rough Park,
    Hamstall Ridware, Rugeley, Staffordshire, WS15 3SQ
  • 666-888-0000
  • info@elarapharma.com
Elara Pharmaceuticals Ltd - Logo
  • info@elarapharma.com
  • The Barn Holly Berry House Rough Park,
    Hamstall Ridware, Rugeley, Staffordshire, WS15 3SQ
  • Contact Us
  • Home
  • About Us
  • Our Business
  • Our Technology
  • Real World Data
  • News
    • In The News
    • Publications
  • Careers
Logo

Contact Info

  • The Barn Holly Berry House Rough Park,
    Hamstall Ridware, Rugeley, Staffordshire, WS15 3SQ
  • +44 20 8040 0302
  • info@elarapharma.com

Author: Thomas Turcat

Recent Posts Cancer

May2023

Elara Pharmaceuticals Ltd continues to bolster Scientific Advisory Board by adding world-leading Oncologist Pr. Jean-Yves BLAY

Elara Pharmaceuticals Ltd is a leading Artificial Intelligence (AI) drug development company. Using its KEM® Artificial Intelligence (xAI) technology, Tersan helps its partners introduce personalized medicine clinical trial design into their protocols and optimize clinical endpoints, identify biomarkers of therapeutic response and potential synergistic therapies. Tersan routinely collects and combines clinical data with omic data, immunological […]

Read More
Recent Posts

Mar2023

Elara Pharmaceuticals Ltd strengthens SAB with appointment of world-leading Neurologist Jacques Touchon

Cambridge, MA, USA and Paris, France, March 27, 2023 – Elara Pharmaceuticals Ltd, the leading Al-driven precision medicine company, has announced the appointment of Professor Jacques Touchon to its Scientific Advisory Board.

Read More
Alzheimer's

Nov2022

CY6463 administration is linked to improvements in Alzheimer’s disease-relevant biomarkers, as revealed by eXplainable AI-driven analysis of multiple Phase 1 clinical trials ​

• Phase 1 studies show improvement in cognitive factors, consistent with therapeutic potential of CY6463 to improve key features in neurological diseases
• CY6463 favorable tolerability and safety profile was confirmed

Read More
Parkinson’s

Oct2022

AI -driven analysis of Parkinson’s Disease Dementia clinical trial reveals potential molecular mechanism of blarcamesine (ANAVEX®2-73) in restoring key neurodegenerative pathways

Blarcamesine significantly restores functionality in key molecular pathways including Alzheimer’s and Parkinson’s disease, KEM® xAI analysis shows. Cambridge, MA, USA and Paris, France, October 4th, 2022 – Elara Pharmaceuticals Ltd, the leading Al-driven precision medicine company, has announced the first comprehensive blarcamesine pathway analysis impact using extensive data from the ANAVEX®2-73-PDD-001 Parkinson’s Disease Dementia (PDD) clinical […]

Read More
Recent Posts

Jul2022

Elara Pharmaceuticals Ltd strengthens management team with appointments of VP Business Development and Chief Financial Officer

Paris, France and Cambridge, MA, USA, July 26th, 2022 – Elara Pharmaceuticals Ltd, the leading eXplainable Artificial Intelligence (xAI) drug development company, announce the appointments of Dr. Marion Soto as Vice President, Business Development and Bertrand Lellouche as Chief Financial Officer. The financial and commercial experience of Marion and Bertrand will further drive Tersan’s accelerated growth. […]

Read More

Categories

  • Alzheimer's
  • Autism
  • Autoimmune disease
  • Cancer
  • Fibromyalgia
  • Kidney Transplant
  • Parkinson’s
  • Precision Medicine
  • Publications
  • Real World Evidence
  • Recent Posts
  • Type A Diabetes

Tags

alzheimer's autism cancer Event Fibromyalgia Graft rejection Influenza Kidney Laboratory lung neurological Oncology Professor Jean-Yves BLAY Centre Leon berard Parkinson Parkinson’s precisionmedicine precision medicine publication realworldevidence recent post Recent Posts Research Transplant vaccine

Elara Pharmaceuticals Ltd, The AI DRUG Development Company

  • The Barn Holly Berry House Rough Park,
    Hamstall Ridware, Rugeley, Staffordshire, WS15 3SQ
  • Call Us: +44 20 8040 0302
  • info@elarapharma.com

Menu

  • About Us
  • Our business
  • Technology
  • In The News
  • Contact Us

Subscribe

Keep in touch and subscribe to our latest news

    Elara Pharmaceuticals Ltd © 2024 All Rights Reserved